Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain

Wahida Rahman*, Claudia S Bauer, Kirsty Bannister, Jean-Laurent Vonsy, Annette C Dolphin and Anthony H Dickenson

Address: Department of Neuroscience, Pharmacology and Physiology, University College London, Gower Street, London, WC1E 6BT, UK

Email: Wahida Rahman* - w.rahman@ucl.ac.uk; Claudia S Bauer - c.bauer@ucl.ac.uk; Kirsty Bannister - kirsty.bannister@ucl.ac.uk; Jean-Laurent Vonsy - j.vonsy@ucl.ac.uk; Annette C Dolphin - a.dolphin@ucl.ac.uk; Anthony H Dickenson - anthony.dickenson@ucl.ac.uk

* Corresponding author

Abstract

Background: Descending facilitation, from the brainstem, promotes spinal neuronal hyperexcitability and behavioural hypersensitivity in many chronic pain states. We have previously demonstrated enhanced descending facilitation onto dorsal horn neurones in a neuropathic pain model, and shown this to enable the analgesic effectiveness of gabapentin. Here we have tested if this hypothesis applies to other pain states by using a combination of approaches in a rat model of osteoarthritis (OA) to ascertain if 1) a role for descending 5HT mediated facilitation exists, and 2) if pregabalin (a newer analogue of gabapentin) is an effective antinociceptive agent in this model.

Further, quantitative-PCR experiments were undertaken to analyse the α2δ-1 and 5-HT3A subunit mRNA levels in L3–6 DRG in order to assess whether changes in these molecular substrates have a bearing on the pharmacological effects of ondansetron and pregabalin in OA.

Results: Osteoarthritis was induced via intra-articular injection of monosodium iodoacetate (MIA) into the knee joint. Control animals were injected with 0.9% saline. Two weeks later in vivo electrophysiology was performed, comparing the effects of spinal ondansetron (10–100 µg/50 μl) or systemic pregabalin (0.3 – 10 mg/kg) on evoked responses of dorsal horn neurones to electrical, mechanical and thermal stimuli in MIA or control rats. In MIA rats, ondansetron significantly inhibited the evoked responses to both innocuous and noxious natural evoked neuronal responses, whereas only inhibition of noxious evoked responses was seen in controls. Pregabalin significantly inhibited neuronal responses in the MIA rats only; this effect was blocked by a pre-administration of spinal ondansetron. Analysis of α2δ-1 and 5-HT3A subunit mRNA levels in L3–6 DRG revealed a significant increase in α2δ-1 levels in ipsilateral L3&4 DRG in MIA rats. 5-HT3A subunit mRNA levels were unchanged.

Conclusion: These data suggest descending serotonergic facilitation plays a role in mediating the brush and innocuous mechanical punctate evoked neuronal responses in MIA rats, suggesting an adaptive change in the excitatory serotonergic drive modulating low threshold evoked neuronal responses in MIA-induced OA pain. This alteration in excitatory serotonergic drive, alongside an increase in α2δ-1 mRNA levels, may underlie pregabalin’s state dependent effects in this model of chronic pain.

Published: 7 August 2009
Molecular Pain 2009, 5:45 doi:10.1186/1744-8069-5-45

Received: 6 April 2009
Accepted: 7 August 2009

This article is available from: http://www.molecularpain.com/content/5/1/45

© 2009 Rahman et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Osteoarthritis (OA), the most common form of arthritis [1,2], is a degenerative joint disease, usually of weight bearing joints (knees and hips), characterized by damage to the articular cartilage and subchondral bone, synovitis and capsular thickening. OA can develop following the loss of joint stability, hence its aetiology is diverse and multifactorial, and is associated with chronic debilitating joint pain, that can range from mild (dull aches) to severe (sharp stabbing pain). While pain is usually the main symptom and the first reason of complaint of OA patients, it is only recently that research into the mechanisms of OA pain has developed.

Current therapies do not include disease modifying drugs, thus analgesics remain as the first line treatment for OA. Starting with paracetamol, treatment is then followed by NSAIDs, opioids and steroids in line with disease progression and increasing pain severity. However, the therapeutic window and the level of pain relief with these therapies is often inadequate in a large proportion of patients. Thus it is important to identify the molecular mechanisms that induce and maintain the pain state in order to develop more effective therapeutic agents.

In OA patients, approximately 60–80% achieve pain relief after local anaesthetic treatment or surgical replacement of the affected joint, indicating peripheral mechanisms driving the pain [3-6], although in some patients central mechanisms are also thought to play a role and dysfunction of diffuse noxious inhibitory controls have been described [7]. These central mechanisms may overlap with those in other pain states such as neuropathy.

Alongside alterations in descending inhibitory controls, descending facilitation from the brainstem has been indicated to be a key mechanism underlying some forms of chronic pain [8-18]. For instance, we have previously demonstrated an enhanced descending facilitation, mediated by brainstem serotonergic pathways acting at pronociceptive spinal 5HT3 receptors, that contributes to the pathophysiologcal changes following nerve injury and cancer induced bone pain [13,19]. Therefore, in the present study the role of descending facilitation in a rat model of OA was assessed.

We have used a chemical model of OA pain, using monosodium iodoacetate (MIA), a glycolysis inhibitor, which has proved a reliable and consistent model of osteoarthritis that mimics pain in OA patients [20-23]. Following a single intra-articular MIA injection into the rat knee joint, a progressive degeneration of cartilage is seen [24] and these changes have been shown to be similar to the human disease [25,26]. Whilst painful symptoms are mostly associated with the area surrounding the affected joint, referred pain and tenderness can also occur in patients [27,28] and is apparent in the MIA rat model as hypersensitive responses to stimulation of the ipsilateral hindpaw [23].

Following a two week OA induction period we assessed the contribution of descending facilitation, using in vivo electrophysiological methods to compare the effects of spinal application of the selective 5HT3 receptor antagonist, ondansetron, on evoked dorsal horn neuronal responses in MIA and control rats. Additionally, we have previously shown that descending facilitation from the brainstem enables the anti-hyperalgesic actions of gabapentin following peripheral nerve injury [29]. This led us to assess the effects of pregabalin (a newer analogue of gabapentin) on spinal neuronal activity in MIA rats, to test whether descending serotonergic facilitation is an important mechanism enabling the analgesic effectiveness of pregabalin in this model of chronic pain. In these studies we have concentrated on secondary hyperalgesia in that we have examined responses evoked from the paw after knee MIA. Gabapentin has state-dependent actions, modulating abnormal activity and has been shown to be effective in human imaging studies in the presence of central sensitization [30].

Results

Following intra-articular injection of MIA or saline, both groups of rats maintained good health, exhibiting normal weight gain and general level of activity with no signs of distress, and the final weight at time of electrophysiology was not different between the MIA (271 ± 7 g) or sham (275 ± 11 g) groups.

Behavioural responses

Probing the ipsilateral hind paw with von Frey hairs and application of acetone revealed behavioural signs of mechanical and cooling hypersensitivity, seen as a significant increase in ipsilateral hind paw withdrawal frequency to stimulation with von Frey filaments 1 & 6 g and acetone application in the MIA group compared with the same responses in the sham-operated group (Fig. 1). Stimuli applied to the contra-lateral hind paw of MIA or sham rats produced little or no evoked hind paw withdrawal responses in either group (data not shown). Similarly, the ambulatory evoked pain score in the MIA rats was higher compared with the vehicle treated sham rats (Fig. 1). This behavioural hypersensitivity observed on the hind paw after MIA injection into the knee is indicative of secondary hyperalgesia and is likely due to central sensitization.

Spinal cord electrophysiology – cell characterization

The evoked responses of ipsilateral deep dorsal horn neurons were characterised in MIA (n = 30) and saline injected sham (n = 34) rats (Table 1). The mean neuronal cell depth was not significantly different between experimental groups and corresponded to lamina V-VI of the
Figure 1
Behavioural assessment from 3 days before until 14 days after MIA (n = 17) or saline injection (n = 16). A. mechanical and B. cooling stimuli applied to the ipsilateral hind paw. C. ambulatory evoked pain score. MIA injection into the knee resulted in behavioural hypersensitivity as evidenced by the significantly greater number of paw withdrawal responses to mechanical punctate and acetone application, and the observed pain scored on ambulation compared with the saline control rats. *p < 0.05, ** p < 0.01 compared with shams.
spinal dorsal horn, thus enabling direct comparison of evoked neuronal responses. All neurones recorded in this study had receptive fields which included at least one toe on the hind paw and were classified as wide dynamic range, since they all responded to both light touch and noxious inputs (pinch and noxious heat), and responded to natural stimuli in a graded manner with increasing intensity.

The evoked neuronal responses to a train of electrical stimulation were not significantly different between groups (Table 1). In contrast, MIA injected rats exhibited an overall enhanced neuronal response, evoked during the 10-second application period, to mechanical stimulation in a stimulus intensity dependent manner; significant effects were seen in response to application of von Frey filaments 8–60 g (P < 0.05) (Fig. 2A). Furthermore, the mechanical evoked neuronal after-discharge, quantified as the total number of action potentials the neurone continued to fire after the removal of the stimulus period was greater in the MIA group (P < 0.03) (Fig. 2B). Enhanced thermal evoked neuronal responses were also seen in the MIA group compared with controls, although this did not quite reach significance (Fig. 2C, D). Thus, these results indicate a general hyperexcitable nature of spinal wide dynamic range neurones in segments adjacent to the primary insult in this model of OA (Fig. 2) indicative of central sensitization.

**Effects of spinal ondansetron administration on the evoked responses of dorsal horn neurones**

Spinal administration of ondansetron did not produce any significant effects on any of the electrically evoked neuronal responses in either the MIA or vehicle treated rats (data not shown). However, the same doses of spinal ondansetron administration resulted in a significant inhibition of some of the natural evoked responses in both groups (Figs. 3 & 4).

In MIA injected rats, spinal ondansetron resulted in a dose-related inhibition of a range of natural evoked responses. The evoked neuronal response to stimulation of the peripheral receptive field with dynamic brush was significantly reduced at 10–100 μg (P < 0.05), and with von Frey 2 and 8 g were significantly reduced at 50 and 100 μg (P < 0.05) in the MIA rats compared with pre-drug control values. Strikingly, in contrast, ondansetron did not produce any significant inhibition of these low threshold evoked responses in the control group (Fig. 3).

With regard to the evoked responses to noxious stimuli similar dose-related inhibitions were seen in MIA and vehicle-treated groups for both mechanical (von Frey 26 and 60 g) (Fig. 3), and thermal (45 and 48°C) modalities (Fig. 4). However, the inhibitory effect of ondansetron at 50 μg on the evoked response to 45°C heat was significantly greater in the MIA group when compared with the effect of the drug in the vehicle treated group (P < 0.05). Ondansetron at 10 μg produced a significant inhibition of the evoked neuronal response to 40°C in the sham control group, an effect not seen in the MIA treated group at this dose. The evoked responses to suprathreshold 50°C stimulation were not significantly altered by ondansetron in either group (Fig. 4).

These findings suggest that OA induces a novel contribution of 5HT3 receptor-mediated excitation of low threshold mechanical (dynamic brush and innocuous mechanical punctate) evoked neuronal responses and an

---

**Table 1: A comparison of the baseline electrophysiological responses of deep dorsal horn neurons in saline (n = 30) and MIA (n = 34) injected rats.**

|                     | Sham (n = 30) | MIA (n = 34) |
|---------------------|--------------|--------------|
| Depth (μm)          | 787 ± 50     | 730 ± 37     |
| Electrically-evoked Responses |
| C-fibre threshold (mA) | 0.76 ± 0.08  | 0.71 ± 0.07  |
| Aβ-fibre evoked response (AP) | 157 ± 14  | 175 ± 13  |
| Aδ-fibre evoked response (AP) | 136 ± 13  | 137 ± 12  |
| C-fibre evoked response (AP) | 401 ± 31  | 475 ± 38  |
| Post discharge (AP) | 257 ± 37     | 265 ± 34     |
| Input (AP)          | 334 ± 52     | 389 ± 37     |
| Wind-up (AP)        | 442 ± 58     | 452 ± 60     |

The electrical evoked responses are expressed as the mean number of action potentials (AP) ± S.E.M. evoked by a train of 16 electrical stimuli given at three times the threshold for C-fibre evoked neuronal response.
enhancement of noxious thermal evoked responses to 45°C in MIA treated rats compared with control animals, since the antagonist was either without effect on these neuronal measures (low threshold mechanical) or had a lesser effect on noxious heat evoked responses (45°C) in the control group.

Effects of systemic pregabalin administration on the evoked responses of spinal dorsal horn neurones

Since gabapentinoids have been shown to exert analgesic effects in a variety of models of hyperalgesia and allodynia [31,32], not simply neuropathy, and because we have previously demonstrated a link between 5HT3 receptor activity and efficacy of gabapentin [29], this led us to investigate the consequences of pregabalin administration on neuronal responses in the MIA model.

Systemic administration of pregabalin produced a significant inhibition of noxious electrical evoked responses in the MIA-treated group only. The A-delta fibre evoked response was clearly inhibited at 3 and 10 mg/kg pregabalin, with a maximum inhibition of 60 ± 11% of the pre-drug control response with the top dose. The C-fibre and post discharge evoked neuronal responses were also

Figure 2
Electrophysiological recordings of deep dorsal horn wide dynamic range neuronal responses in MIA (n = 30) and sham rats (n = 34). A) Mean evoked neuronal response of peripheral mechanical stimulation during the 10 second application period. B) Mean after-discharge response of neurons to mechanical stimulation. C) Mean evoked neuronal response of peripheral thermal stimulation during the 10 second application period. D) Mean after-discharge response of neurons to thermal stimulation. MIA injection resulted in an overall increase in neuronal excitability. * p < 0.05 compared with sham control data.
Comparison of the effects of spinal administration of ondansetron on the evoked neuronal responses to dynamic brush and mechanical punctate stimulation in sham (n = 8) and MIA (n = 8) rats. The neuronal responses evoked by dynamic brush, von Frey 2 and 8 g stimulation were significantly reduced by 50 and 100 μg of ondansetron in the MIA group. Ondansetron produced no significant effects on the mechanical evoked neuronal responses in the sham group. *p < 0.05 compared with pre-drug baseline control data.
inhibited by the drug but to a much lesser extent, with a significant reduction compared to pre-drug control responses seen only at 10 mg/kg (Fig. 5).

The mechanical and thermal evoked responses in the MIA rats were inhibited similarly in a dose-related manner (P < 0.05, 1-way ANOVA) (Fig. 6 & 7). In comparison, pregabalin produced no significant effects on any of the natural stimuli evoked neuronal measures in the sham controls when compared with pre-drug control neuronal responses, (Fig. 5, 6, 7) illustrating state-dependency of the drug.

**Antagonism of spinal 5-HT3 receptors results in the loss of pregabalin’s inhibitory effects**

To test whether the active participation of spinal 5-HT3 receptors is a requirement for the efficacy of pregabalin in MIA rats, we assessed the effects of the top dose of pregabalin (10 mg/kg) in a separate group of MIA rats that had been pre-treated with spinal ondansetron. This dose of pregabalin alone produced significant neuronal inhibitions in the MIA group, but in the presence of ondansetron no longer produced any significant effects, indicating a loss of pregabalin efficacy following 5-HT3 receptor blockade (Fig. 8A, B).

### Up-regulation of α2δ-1 subunit in L3 + L4 DRG of MIA treated rats

Up-regulation of α2δ-1 subunit levels has been suggested to be correlated with the onset of allodynia and with the analgesic efficacy of gabapentinoids in a variety of models of chronic pain, such as spinal nerve ligation, HIV and chemotherapy induced neuropathies [33-39], but not in a model of radicular pain, where gabapentin still produced...
antinociception [40]. Therefore we measured the levels of mRNA for the α2δ-1 subunit in the L3 – L6 DRGs to assess whether or not there was a comparable relationship in the OA model. A small but significant increase was seen in the mRNA level for the α2δ-1 subunit in the ipsilateral L3 + 4 DRG (135 ± 16%) when compared with sham controls (p < 0.05, un-paired t-test). An increase in α2δ-1 mRNA expression was also seen for the ipsilateral L5 + 6 DRG (121 ± 28%) when compared with the appropriate contralateral DRGs although this change did not reach significance (Fig. 8C).

5-HT3A receptor subunit mRNA levels in lumbar DRG in MIA rats

Expression levels of the 5HT3A subunit mRNA were unchanged in the ipsilateral L3–L6 DRG compared with the contralateral side (Fig. 8D), indicating that the altered effects of 5HT3 receptor blockade are likely to be due to greater physiological activity in the descending pathways in the MIA animals and not receptor changes.

Discussion

OA is a disease with diverse originating factors; these include a progressive degeneration of the articular cartilage, subchondral bone and weakness of joint muscles in concert with inflammatory episodes within the joint. In OA patients the pain experience is largely use-dependent and relates to the area surrounding the affected joint, however areas of referred pain also exist, for instance muscle hyperalgesia and expansion of peripheral receptive field area for pain has been demonstrated in OA patients, indicative of central sensitisation [28]. Thus pain in OA bears similarities with other chronic pain conditions, in that a variety of abnormal cellular mechanisms, both peripheral and central, underpin the pathology.

Intra-articular injection of MIA into the knee joint features pathophysiological and behavioural indices aligned with the human pain experience of OA [20-26].

Our findings corroborate earlier reports, with MIA rats displaying behavioural hypersensitive responses seen as
Effects of systemic injection of pregabalin on the evoked neuronal responses to mechanical stimulation of the peripheral receptive field. Pregabalin produced significant inhibition of dynamic brush and mechanical punctate evoked neuronal responses in the MIA treated group (n = 9) compared with pre-drug baseline responses. The drug produced little or no effect in the sham control group (n = 8). Data are expressed as the mean percentage of pre-drug control values ± S.E.M. * p < 0.05 significant difference compared with pre-drug baseline control data.
high scores for ambulatory evoked pain and increased hind paw withdrawals to stimulation of the hind paw with von Frey filaments/acetone that had no effect on the contralateral side or in sham controls. This behavioural hypersensitivity to stimulation of the referred receptive field area is indicative of secondary hyperalgesia, which has also been reported in OA patients [23,27,28]. Furthermore, an overall increase in the baseline neuronal responses, in terms of the total number of action potentials evoked during the mechanical and thermal stimulation application period and the after-discharge response (total number of action potentials occurring after the 10-second mechanical or thermal stimulation period) is evident in the MIA group, providing evidence for central sensitization in these animals, which in turn may underlie the observed behavioural hypersensitivity. This type of hyper-responsiveness of neuronal activity has been demonstrated in a mouse model of MIA-induced OA pain [41] and in another rat model of monoarthritis [42,43].

Many studies have demonstrated a critical contribution of descending facilitation, arising from brainstem areas such as the rostral ventromedial medulla (RVM), in the development and maintenance of central sensitisation in other models of persistent pain, since pharmacological or anatomical disruption of this pathway attenuates the behavioural hypersensitivity associated with inflammatory, nerve injury and visceral models of pain, and reduces the excitability of wide dynamic range dorsal horn neurones in both acute and chronic pain states [8-18,29,44,45].

**Figure 7**
Effects of systemic injection of pregabalin on the evoked neuronal responses to thermal stimulation of the peripheral receptive field. Pregabalin significantly inhibited the thermal evoked neuronal responses in the MIA group (n = 9) compared with pre-drug baseline responses. The drug produced little or no effect in the sham control group (n = 8). Data are expressed as the mean percentage of pre-drug control values ± S.E.M. * p < 0.05 significant difference compared with pre-drug baseline control data.
Descending pain facilitation arising from the RVM requires the activation of pronociceptive ON cells [15, 46], and sensitization of RVM ON cells, which was correlated with behavioural hypersensitivity, has been demonstrated in neuropathic rats [47]. Furthermore, electrophysiological evidence from spinal cord recordings suggests activity in descending excitatory pathways is enhanced after peripheral nerve injury as demonstrated by a greater sensitivity of dorsal horn neurones to inhibition by spinal administration of ondansetron or intra-RVM administration of lignocaine [16, 19]. We show here that topical spinal application of ondansetron produced marked inhibition of the evoked neuronal responses to dynamic brush and mechanical punctate stimulation in the MIA group, an effect not observed in the control group. These electrophysiological findings correlate with a recent study that demonstrated the role of spinal 5-HT3 receptors in pain modulation.

Figure 8
A and B. Comparison of the effects of pregabalin alone or in the presence of ondansetron on the evoked neuronal responses to mechanical punctate (A) and thermal stimulation (B) of the peripheral receptive field in MIA rats (n = 7). Pregabalin alone significantly inhibits the natural evoked neuronal responses. This inhibitory effect of the drug is lost when spinal 5-HT3 receptors are blocked. Data are expressed as the mean percentage of pre-drug control values ± S.E.M. * p < 0.05 significant difference compared with pre-drug baseline controls.

C. Quantification of α2δ-1 and 5-HT3A subunit mRNA levels in ipsilateral relative to contralateral DRGs following MIA or saline injection. (C). Mean data for Q-PCR of α2δ-1 in pooled ipsilateral L3/L4 DRGs (ipsi 3+4) or pooled ipsilateral L5/L6DRGs (ipsi 5+6) from either sham (n = 10 and n = 9 respectively) or MIA animals (n = 15 or n = 7 respectively) 14 days after injection. (D). Mean data for Q-PCR of 5-HT3A in pooled ipsilateral L3/L4 DRGs (ipsi 3+4) or pooled ipsilateral L5/L6DRGs (ipsi 5+6) from either sham (n = 7 and n = 7 respectively) or MIA animals (n = 11 or n = 7 respectively). Data are normalized to the respective contralateral side and expressed as the mean percentage of control values ± S.E.M. * p < 0.05 significant difference compared with sham controls.
behavioural study where the antinociceptive effectiveness of ondansetron (10 μg) was demonstrated [48].

There are a number of reports demonstrating a serotonergic facilitatory effect onto the spinal cord [44,49] through engagement of pronociceptive spinal 5-HT3 receptors in models of acute and chronic pain, with most studies using neuropathic models [12,15,17,29,50-52]. Pharmacological antagonism of physiological responses reveals the role of released transmitter acting on a particular receptor, which will depend on activity in related neuronal pathways. Thus the novel inhibitory effects of ondansetron on low threshold mechanical responses in the MIA treated group suggests adaptive changes in the activity in serotonergic pathways.

Functional 5-HT3Rs require the presence of the 5HT3A subunit [53,54], and as we did not observe any significant changes in 5HT3A receptor mRNA levels in the ipsilateral DRG of MIA rats it is unlikely that alterations in 5HT3R expression is responsible for the greater inhibitory effect of ondansetron in MIA-injected rats. Thus the data presented here suggests that increased functionality, likely augmented 5HT release, at pronociceptive spinal 5-HT3Rs is one molecular mechanism for central sensitisation underpinning the behavioural hypersensitivity seen in this model of OA pain.

The spinal source of 5-HT arises largely from the RVM (see [55]), and it is well documented that descending serotonergic influences from this brainstem area elicits bi-directional effects on spinal neurones. The facilitatory and inhibitory effects from the RVM are mediated through recruitment of RVM ON or OFF cells respectively, and inhibitory effects from the RVM are mediated through functional effects on spinal neurones. The facilitatory and chronic pain. Interestingly, in the MIA model the induction of 5HT3 receptor mediated facilitatory events exerted on low-threshold mechanical responses was observed suggestive of a facilitatory drive contributing to secondary hyperalgesia, which is characterized by static mechanical responses.

Systemic administration of pregabalin resulted in inhibition of the noxious evoked electrical evoked responses and also the innocuous and noxious natural evoked responses in the MIA treated rats only. A recent behavioural study by our group using the alpha2delta ligand gabapentin showed modalities of hyperalgesia being altered by gabapentin in the MIA induced model of OA pain [23]. Thus, these findings add to the growing body of evidence demonstrating the state-dependent effects of ligands at the α2δ-1 subunit of voltage gated calcium channels (VGCCs), actions which include unique alterations in the trafficking of the α2δ-1 subunit [39].

The mechanism by which gabapentinoids are able to target a ubiquitous subunit present in all VGCCs in pathophysiological states to provide analgesia yet be without antinociceptive effect under normal physiological conditions remains unclear. Alterations in VGCC function are likely to play a role, for instance N-type calcium channels acquire greater functional roles after nerve injury [59,60] and evidence exists for an upregulation of the α2δ-1 subunit and the N-type pore-forming α1B subunit in this pain state, which is proposed to correlate with the development of tactile allodynia and relate to the injury-specific action of gabapentin [33,35-39,61,62]. In line with this hypothesis, transgenic mice that constitutively but globally over-express the α2δ-1 subunit in neuronal tissues resulted in enhanced currents, altered kinetics and voltage-dependence of VGCC activation in sensory neurons; exaggerated and prolonged dorsal horn neuronal responses to peripheral mechanical and thermal stimulations; and pain behaviours [63,64].

In the present study, we observed an increase in α2δ-1 subunit mRNA expression in the DRG receiving afferents from the knee of the MIA group, which was comparable to findings in models of chemotherapy and varicella zoster virus induced neuropathies (approx. 46% and 38% increase respectively), and gabapentin alleviated the behavioural measures of hypersensitivity in these neuropathic animals. [34,36]. After peripheral nerve injury the upregulation is much greater in magnitude [38,39] and restricted to the denervated DRG segment which suggests that the effects of gabapentin and pregabalin on evoked responses may involve additional factors.

Thus our findings with spinal ondansetron in the MIA model of OA pain support previous reports and highlight the crucial link between descending serotonergic facilitation and chronic pain. Interestingly, in the MIA model the induction of 5HT3 receptor mediated facilitatory events exerted on low-threshold mechanical responses was observed suggestive of a facilitatory drive contributing to secondary hyperalgesia, which is characterized by static mechanical responses.

Systemic administration of pregabalin resulted in inhibition of the noxious evoked electrical evoked responses and also the innocuous and noxious natural evoked responses in the MIA treated rats only. A recent behavioural study by our group using the alpha2delta ligand gabapentin showed modalities of hyperalgesia being altered by gabapentin in the MIA induced model of OA pain [23]. Thus, these findings add to the growing body of evidence demonstrating the state-dependent effects of ligands at the α2δ-1 subunit of voltage gated calcium channels (VGCCs), actions which include unique alterations in the trafficking of the α2δ-1 subunit [39].

The mechanism by which gabapentinoids are able to target a ubiquitous subunit present in all VGCCs in pathophysiological states to provide analgesia yet be without antinociceptive effect under normal physiological conditions remains unclear. Alterations in VGCC function are likely to play a role, for instance N-type calcium channels acquire greater functional roles after nerve injury [59,60] and evidence exists for an upregulation of the α2δ-1 subunit and the N-type pore-forming α1B subunit in this pain state, which is proposed to correlate with the development of tactile allodynia and relate to the injury-specific action of gabapentin [33,35-39,61,62]. In line with this hypothesis, transgenic mice that constitutively but globally over-express the α2δ-1 subunit in neuronal tissues resulted in enhanced currents, altered kinetics and voltage-dependence of VGCC activation in sensory neurons; exaggerated and prolonged dorsal horn neuronal responses to peripheral mechanical and thermal stimulations; and pain behaviours [63,64].

In the present study, we observed an increase in α2δ-1 subunit mRNA expression in the DRG receiving afferents from the knee of the MIA group, which was comparable to findings in models of chemotherapy and varicella zoster virus induced neuropathies (approx. 46% and 38% increase respectively), and gabapentin alleviated the behavioural measures of hypersensitivity in these neuropathic animals. [34,36]. After peripheral nerve injury the upregulation is much greater in magnitude [38,39] and restricted to the denervated DRG segment which suggests that the effects of gabapentin and pregabalin on evoked responses may involve additional factors.

Indeed, upregulation of the α2δ subunit, is not the only determinant of the selective antinociceptive effects of gabapentinoids as the converse has also been shown, i.e.
reversal of allodynic behaviour with gabapentin occurs in the absence of $\alpha_2\delta-1$ subunit upregulation [40] and behavioural hyperalgesia can be observed as early as 1 day after peripheral nerve injury [65], whilst $\alpha_2\delta-1$ upregulation is only evident after 7 days [37]. Another mechanism proposed to be permissive for the antinociceptive effectiveness of $\alpha_2\delta-1$ ligands and their ability to differentiate pathological states is the increased active participation of descending serotonergic facilitation of spinal neuronal activity via activation of spinal 5-HT3 receptors [19,29]. Interruption of descending facilitation resulted in a loss of antinociceptive effectiveness of gabapentin/pregabalin in neuropathic rats [17,29], whilst activating spinal 5-HT3 receptors in naïve control animals enabled gabapentin to produce marked inhibitions of evoked neuronal activity where previously, in the absence of 5-HT3 activation, the drug had little or no effect [29]. In healthy humans, capsaicin induced hyperalgesia is sensitive to gabapentin in terms of both psychophysics and fMRI activation in brainstem and other brain areas, conditions where no time for upregulation of the $\alpha_2\delta-1$ subunit could occur [30,66]. The findings of the present study parallel those seen in the spinal nerve ligation model and lend support for the concept that serotonergic circuits play a role in regulating the state dependent inhibition of neuronal responses in these animals. The novel and increased neuronal activity and behavioural hypersensitivity observed in the MIA group, indicating a link between central sensitisation, a feature of many chronic pain states, in osteoarthritis. Finally, spinal ondansetron prevented the antinociceptive actions of pregabalin, suggesting that descending facilitation, alongside the upregulation in the expression of $\alpha_2\delta-1$ subunit of VGCCs, is an important mechanism which enables the inhibitory actions of pregabalin in this model of OA pain.

OA represents one of the largest clinical costs to healthcare in the western world [67]. The associated pain is the main symptom of complaint in patients with a pan-European survey showing that nearly a third of patients suffering from chronic pain presented with OA as the primary cause [68]. Therefore unraveling the cellular and molecular mechanisms underlying the pain state is of major clinical importance in the development of more clinically effective drugs.

**Methods**

**Induction of Osteoarthritis**

Osteoarthritis was induced by injecting 2 mg monosodium iodoacetate in 25 $\mu$l of 0.9% saline through the infrapatellar ligament of the knee in anaesthetised Sprague Dawley rats (130–150 g). Sham animals were injected with sterile 0.9% saline only. Following injection animals were allowed to recover and then re-housed in cages under a 12-h alternating light/dark cycle with ad libitum access to food and water.

**Behavioural assessment**

Behavioural responses to mechanical and cooling stimulation of the ipsi- and contralateral hind paws were recorded over a two-week period, as was performance on a rotarod. Briefly, animals were left to acclimatize to the testing area for 30 min before testing, sensitivity to mechanical punctate stimulation was then assessed through measurement of the number of foot withdrawal responses to a trial of 10 applications of calibrated von Frey filaments with increasing bending force of 1 and 6 g to the plantar surface of each hind paw. Cold sensitivity was similarly assessed as the number of withdrawals out of a trial of 5 applications of a drop of acetone to the plantar surface of ipsilateral and contralateral hind paws. Withdrawal frequency was quantified as = (number of foot withdrawals/10 or 5 trials as appropriate).

Behavioral signs of ambulatory-evoked pain were assessed preoperatively and on postoperative days -3, 2, 4, 7, 9 11 and day 14 using the Ugo Basile model 7750 Rotarod (Linton Instruments, Diss, Norfolk, UK). The apparatus was set to accelerate from 0–20 revolutions per minute (rpm) over 60 s and the time maintained on the beam before falling was recorded (with a maximum cut-off of 180 s). The general ambulation of the animal was also observed and scored as follows: 0 = no limp, 1 = slight limp, 2 = marked limp and decreased use of ipsilateral limb and 3 = avoidance of use of ipsilateral limb. Previous studies from our laboratory have validated the use of the rotarod test as a reliable means for assessing ambulatory evoked pain [23,69–71]. Only rats scoring between 60 and 120 s in training sessions before surgery were used for experimentation.

**Electrophysiology**

Two weeks after MIA injection in vivo electrophysiological studies were performed (post-operative days 15 – 19) as previously described. Briefly, animals were anesthetised
and maintained for the duration of the experiment with isoflurane (1.5–1.7%) delivered in a gaseous mix of N₂O (66%) and O₂ (33%). A laminectomy was performed to expose the L4–5 segments of the spinal cord. Extracellular recordings were made from ipsilateral deep dorsal horn neurones (lamina V-VI) using parylene coated tungsten electrodes (A-M Systems, USA). All the neurones recorded in this study were WDR since they all responded to both light touch and noxious inputs (pinch and noxious heat); further all neurones responded to natural stimuli in a graded manner with coding of increasing intensity.

The evoked response to a train of 16 transcutaneous electrical stimuli (2 ms wide pulses, 0.5 Hz) applied at 3 times the threshold current for C-fibre activation of the dorsal trical stimuli (2 ms wide pulses, 0.5 Hz) applied at 3 times the threshold current for C-fibre activation of the dorsal horn cell. The train of electrical stimuli was delivered via stimulating needles inserted into the peripheral receptive field, following which a post-stimulus histogram was consed. Responses evoked by Aβ – (0–20 ms), Aδ – (20–90 ms) and C-fibres (90–350 ms) were separated and quantified on the basis of latency. Responses occurring after the C-fibre latency band were taken to be the post-discharge of the cell (350–800 ms).

The centre of the peripheral receptive field was also stim-ulated using mechanical punctate and thermal stimuli (von Frey filaments, 2, 8, 26 and 60 g and heat, applied with a constant water jet, 35, 40, 45, 48 and 50°C) Application of each von Frey hair was separated by a minimum interval period of 5 10 seconds, and longer for very responsive neurons at the higher intensity range. Application of each subsequent heat stimulus was separated by a minimum period of 1 minute. All natural stimuli were applied for a period of 10 seconds per stimulus. Data was captured and analysed by a CED 1401 interface coupled to a Pentium computer with Spike 2 software (Cambridge Electronic Design; PSTH and rate functions).

On average, between 1 to 3 neurones were recorded from each animal in order for their baseline responses to peripheral stimuli (detailed above) to be characterized. Pharmacological assessment was carried out on the final neuron recorded in each animal, i.e. a drug study was car-ried out on one neuron only per animal. The testing procedure was carried out every twenty minutes and consisted of a train of electrical stimuli followed by natural stimuli as described above. Following three consecutive stable control trials (< 10% variation for the C-fibre evoked response, and < 20% variation for all other parameters) neuronal responses were averaged to give the pre-drug drug control values.

**Drug administration**

Ondansetron (Zofran TM Glaxo-Wellcome) was diluted with 0.9% saline solution to give doses of 10, 50 and 100 μg/50 μl, and was administered via topical spinal application with a Hamilton syringe. Pregabalin (a gift from Pfizer, Sandwich, UK) was dissolved in 0.9% saline solution to give doses of 0.3, 3 and 10 mg/kg, which were administered via subcutaneous injection in the scrub of the back of the neck.

The effect of each dose (ondansetron or pregabalin) was followed for over an hour, with tests carried out at 20, 40 and 60 minutes before subsequent drug applications were made and effects again followed for an hour.

**Quantitative PCR – α₂δ-1 and 5-HT3 receptor subunit mRNA levels**

Pain associated with peripheral nerve injury and also the analgesic efficacy of gabapentinoids has been correlated with a marked upregulation of the α₂δ-1 subunit of voltage gated calcium channels in rats [33,35,37-39]. Furthermore there is evidence for neuropathic pain associated with osteoarthritis [72]. Therefore we analysed the α₂δ-1 subunit mRNA levels in DRG for the primary afferents innervating the knee joint and hindpaw (L3–L6) in MIA rats. Additionally, the 5-HT3A subunit mRNA was similarly quantified. We verified that the knee afferents arise from L3 (5.2% of total cells) and L4 (2.9%) as compared to L5 (0.5%) by counting labelled cells after intra-articular injection of Fast Blue (10 μl 1%).

Following the last behavioural testing day (post injection day 14), MIA-treated animals were decapitated and L3–6 DRGs ipsilateral and contralateral to injection were har-vested and kept at -80°C. The methods for quantitative PCR (Q-PCR) were essentially as described previously (Donato et al., 2006). Briefly, RNA was extracted from ipsi- or contralateral L3 – L6 pulverized frozen DRGs, 14 d after injection of MIA or saline into the knee joint. RNA was isolated using RNeasy columns (Qiagen), including an on-column DNase step. Reverse transcription was car-ried out on 1 μg RNA using the iScript kit with random primers (BioRad, Hercules, CA). Q-PCR was performed with an iCycler (BioRad) using the iQ SYBR supermix (Biorad). For each set of primers and for every experiment a standard curve was generated using a serial dilution of reverse-transcribed RNA from the combined samples. The following Q-PCR primers were used: rat GAPDH (AF106860) 5’-ATGACTCTCCACCCAGCGCAAG-3’ (forward), 5’-CATACTTGCCACCAGCATCTC-3’ (reverse); rat α₂δ-1 (NM012919) 5’-AGGCTATGCGCCAATCACC-3’, 5’-AGTCATCCTCTTCCATAC-3’; rat 5HT3A (NM024394) 5’-AGCCCTGACATCTATAACTTC-3’, 5’-TCCGACCTCACTTCTTG-3’.

**Data analysis**

All data are presented as mean ± standard error of mean (S.E.M.). Behavioural data were analysed using the non-
parametric Mann-Whitney U-test. Analysis of electrophysiological was as follows: Differences between groups with respect to pre-drug baseline responses were analysed using unpaired Student’s t-test to compare the cell depth and electrically evoked responses; a two-way ANOVA followed by Bonferroni post-hoc test was used to compare the baseline mechanical and thermal evoked neuronal responses. Drug effects were expressed as the mean maximal evoked neuronal response for each dose. A one-way analysis of variance with repeated measures (RM-ANOVA) was used to evaluate drug effects (ondansetron or pregabalin) on the evoked responses to each stimulus (electrical, mechanical and heat) in MIA or vehicle treated rats. Where a significant effect was seen with increasing dose, Dunnett’s post hoc tests where then used to assess individual dose effects compared with pre-drug baseline controls. An unpaired t-test on normalised data was used to compare drug effects between experimental groups. Analysis of Q-PCR data was as follows: For each set of primers and for every experiment a standard curve was generated using a serial dilution of reverse-transcribed RNA from the combined samples. Data were normalized for expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Data from the ipsilateral DRG were then normalized to their respective contralateral DRG and given as the mean ± SEM. The cell bodies of the primary afferents supplying the knee joint predominate in L3 & L4 DRG and the L5 & 6 DRG are representative predomnantly of afferent cell bodies of the referred receptive field area, therefore the q-PCR data was pooled into two groups (L3+L4 and L5+L6). Statistical significance between OA and sham animals was determined by a Student’s un-paired t-test. All statistical testing was performed by using Prism 4.0 software (Graphpad/Prism, San Diego, Calif). Level of significance was set at * P < 0.05.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
WR and AHD conceived, designed and performed the experiments, analysed and wrote the manuscript. CSB performed and analysed some of the experiments. KB and JLV formed and analysed some of the experiments. KB and JLV conceived, designed and performed the experiments, analysed and wrote the manuscript. CSB performed and wrote the manuscript. CB performed and analysed some of the experiments. KB and JLV conceived, designed and performed the experiments and wrote the manuscript. CB performed and wrote the manuscript. CSB performed and analysed some of the experiments. KB and JLV conceived, designed and performed the experiments and wrote the manuscript. CB performed and wrote the manuscript. CSB performed and analysed some of the experiments. "We would like to thank Stephen P Hunt for providing helpful discussion."

Acknowledgements
This work was supported by the Wellcome Trust Research Grant 080506/Z/06/Z, BBSRC Research Grant H3111501, NIH Research Grant Y481862(2R01-DA012656-05A2) and INTAS Project 05-1000008-8061. We would like to thank Stephen P Hunt for providing helpful discussion.

References
1. WHO: The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. WHO 2003, 919(1–x):1-218.
2. Felton DT: An update on the pathogenesis and epidemiology of osteoarthritis. Radiologic clinics of North America 2004, 42(1):1-9.
3. Kosek E, Ordeberg G: Lack of pressure pain modulation by heterotypic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2000, 88(1):69-78.
4. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH: Supraneural NK1-expressing neurons control spinal excitability through activation of descending pathways. Nature neuroscience 2002, 5(12):1319-26.
5. Combe R, Bramwell S, Field MJ: The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? Neuroscience letters 2004, 370(2–3):236-40.
6. Fernihough J, Gentry C, Malangoni M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J: Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 2004, 112(1–2):83-93.
7. Porreca F, Ossipov MH, Gebhart GF: Spinal serotoninergic receptors mediate facilitation of a nociceptive reflex by subcutaneous formalin injection into the hindpaw in rats. Brain research 1998, 798:46-54.
8. Urban MO, Gebhart GF: Supraspinal contributions to hyperalgesia. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(14):7687-92.
9. Bergss SE, Gardell LR, Ossipov MH, Malan TP Jr, Vandersch L, Lai J, Porreca F: Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 2002, 22(12):5129-36.
10. Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary descending facilitation. Trends in neurosciences 2002, 25(6):319-25.
11. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH: Supraneural NK1-expressing neurons control spinal excitability through activation of descending pathways. Nature neuroscience 2002, 5(12):1319-26.
12. Donovon-Rodriguez T, Urs CE, Dickenson AH: Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain. Neuroscience letters 2006, 393(2–3):227-42.
13. Rhay JH, Suzuki R, Rahman W, Wong Y, Vonsy JL, Sandhu H, Webber M, Hunt SP, Dickenson AH: Local and descending circuits regulate long-term potentiation and zif268 expression in spinal neurons. The European journal of neuroscience 2006, 24(3):761-72.
14. Veras-Portocarrero LP, Xie JY, Kawalj J, Ossipov MH, King T, Porreca F: Descending facilitation from the rostral ventromedial medulla maintains visceral pain in rats with experimental pancreatitis. Gastroenterology 2006, 130(7):2155-64.
15. Bee LA, Dickenson AH: Rostral ventromedial medulla control of spinal sensory processing in normal and pathophysiological states. Neuroscience 2007, 147(3):786-93.
16. Bee LA, Dickenson AH: Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain 2008, 140(1):209-23.
17. Wei F, Guo W, Zou S, Ren K, Dubner R: Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci 2008, 28(42):10482-95.
18. Suzuki R, Rahman W, Hunt SP, Dickenson AH: Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurons following peripheral nerve injury. Brain research 2004, 1019(1–2):68-76.
19. Pomonis JD, Boulet JM, Gottshalk SL, Phillips S, Sellers R, Burton E, et al: Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 2005, 114(3):339-46.
20. Vonsy JL, Ghandehari J, Dickenson AH: Differential analgesic effects of morphine and gabapentin on behavioural meas-
ures of pain and disability in a model of osteoarthritis in rats. European journal of pain (London, England) 2008 in press.

24. Kalbeh DA: Chemical model of osteoarthritis – a pharmacological evaluation. The journal of rheumatology 1987, 14(Spec No):30:1.

25. Guingamp C, Geggout-Pottie P, Philippe L, Terlain B, Nettet P, Gillet P: Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis and Rheumatism 1997, 40(9):1670-9.

26. Janusz MJ, Hookfin EB, Heitmayr SA, Woessner JJ, Freemont AJ, Hoyland JA, Brown KK, Hsei L, Almstead NG, Pikul S, Taiwo YO: Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society 2001, 9(8):751-60.

27. Farrell M, Gibson S, McMeelen J, Helme R: Pain and hyperalgesia in osteoarthritis of the hands. The Journal of Rheumatology 2000, 27(6):1406-10.

28. Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L: Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain 2001, 93:107-14.

29. Suzuki R, Rahman W, Rygh LJ, Dickenson AH: Sensitization of spinal serotoninergic circuits in regulating neuropathic pain and its treatment with gabapentin. Pain 2005, 117(3):292-303.

30. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, Vennart W, Tracey I: Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(50):18195-200.

31. Field MJ, Li Z, Schwartz JB: Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain. Journal of medicinal chemistry 2005, 48(14):5398-407.

32. Chiechio S, Zammataro M, Caraci F, Rampello L, Copani A, Sabato AF, Nicoletti F: Pregabalin in the treatment of chronic pain: an overview. Clinical drug investigation 2009, 29(3):203-13.

33. Li CY, Song YH, Higuera ES, Luo ZD: Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 2004, 24(9):8494-9.

34. Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin MJ, Kincgton PR, Krah DL, Abbildie C, Fleetwood-Walker SM: Varicella zoster virus induces neuropathic changes in rats dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain 2005, 118(1–2):97-111.

35. Maneuf YP, Luo ZD, Lee K: Alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Seminars in cell & developmental biology 2006, 17(5):565-70.

36. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H: inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. The journal of pharmacology and experimental therapeutics 2006, 318(2):735-40.

37. Luo ZD, Chapman SR, Higuera ES, Sorkin SA, Stauderman K, Williams AF, Dickenson AH, Lujan R, Dolphin AC: The increased trafficking of dorsal horn neuronal responses in a rat model of neuropathic pain. J Neurosci 2001, 21(6):1868-75.

38. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Harvey VL, Dickenson AH: Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57BL/6 mice. Molecular Pain 2009, 5:18.

39. Sharif Naini E, Caihui CM, Ribeiro-da-Siiva A, Menard HA, Henry JL: Remodelling of spinal nociceptive mechanisms in an animal model of monoarthritis. The European journal of neuroscience 2005, 22(8):2005-15.

40. Martindal JC, Wilson AW, Reeve AJ, Chessel IP, Headley PM: Chronic secondary hypersensitivity of dorsal horn neurones following inflammation of the knee joint. Pain 2007, 131(1–2):189–96.

41. Geranton SM, Fratto V, Tochiki KK, Hunt SP: Descending serotoninergic controls regulate inflammation-induced mechanical sensitivity and methyl-Cpg-binding protein 2 phosphorylation in the rat superficial dorsal horn. Molecular Pain 2008, 4:35.

42. Marangell B, Vaughan, Török, Ivascu A: Critical role of the rostral ventromedial medulla in early spinal events leading to chronic constrictin injury neuropathy in rats. J Pain 2008, 9(6):532-42.

43. Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP, Ossipov MH, Lippi DA, Lai J: Inhibition of neuropathic pain by selective ablation of medullary cells expressing the mu-opioid receptor. J Neuroscience 2001, 21(14):5281-8.

44. Carlson JD, Maire JJ, Martensson ME, Heinricher MM: Sensitization of pain-modulating neurones in the rostral ventromedial medulla after peripheral nerve injury. J Neuroscience 2007, 27(23):6322-31.

45. Dogrul A, Ossipov MH, Porreca F: Differential mechanisms of descending pain facilitation and inhibition by spinal SHT-3 and SHT-7 receptors. Brain research 2009, 1280:52-9.

46. Svensson CI, Tran TK, Fitzsimmons B, Yaksh TL, Hua XY: Descending serotoninergic facilitation of spinal ERK activation and pain behavior. FEBS letters 2006, 580(28–29):6629-34.

47. Owatay MA, Chen Y, Weaver LC: The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 2004, 110(1–2):259-68.

48. Rahman W, Suzuki R, Rygh LJ, Dickenson AH: Descending serotonergic facilitation mediated through spinal 5HT3 receptors is unaltered following carrageenan inflammation. Neuroscience letters 2004, 361(1–3):229-31.

49. Rahman W, Suzuki R, Webber M, Hunt SP, Dickenson AH: Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligation. Pain 2006, 121(3):264-74.

50. Davies PA, Pitsos M, Hanna MC, Peters JA, Lambert J, Hales TG, Kirkness EF: The 5-HT3-B receptor is a major determinant of serotonin receptor function. Nature 1999, 397(6717):359-63.

51. Dubin AE, Huvra R, D’Andrea MR, Piati J, Zhu Y, Joyce KC, Wilson SJ, Galindo E, Glass CA, Luo L, Jackson MR, Loyenberg TW, Erlander MG: The pharmacological and functional characteristics of the serotonin 5-HT3-B receptor are specifically modified by a 5-HT3B receptor subunit. The Journal of biological chemistry 1999, 274(43):30799-810.

52. Miller MJ: Descending control of pain. Progress in neurobiology 2002, 66(6):335-474.

53. Marangell S, Vaughan OW, Schnall SA, Wessendorf MW, Christie MJ: Rostral ventromedial medulla neurons that project to the spinal cord express multiple opioid receptor phenotypes. J Neuroscience 2002, 22(24):10847-55.

54. Braz JM, Basbaum AI: Genetically expressed transneuronal tracer reveals direct and indirect serotonergic descending control circuits. The Journal of comparative neurology 2008, 507(4):1990-2003.

55. Potrebic SB, Fields HL, Mason P: Serotonin immunoactivity is contained in one physiological cell class in the rat rostral ventromedial medulla. J Neuroscience 1994, 14(3 Pt 2):1653-65.

56. Yamamoto T, Sakashita Y: Differential effects of intracerebroventricularly administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. Brain research 1998, 794(2):239-52.

57. Matthews EA, Dickenson AH: Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 2001, 92(1–2):235-46.

58. Cizkova D, Marsala M, Stauderman K, Yaksh TL: Calcium channel α1B subunit in spinal cord/DRG of normal and nerve-injured rats. In 9th World Congress on Pain 1999 Edited by: Cizkova D, Marsala M, Stauderman K, Yaksh T. Vienna IASP Press; 1999:134.

59. Boroujerdi A, Kim HK, Lyu YS, Kim DS, Figueroa KW, Chung JM, Luo ZD: Injury discharges regulate calcium channel alpha-2-
delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain. Pain 2008, 139(2):358-66.

63. Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, et al.: Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006, 125(1–2):20-34.

64. Nguyen D, Deng P, Matthews EA, Kim DS, Feng G, Dickenson AH, et al.: Enhanced pre-synaptic glutamate release in deep-dorsal horn contributes to calcium channel alpha-2-delta-1 protein-mediated spinal sensitization and behavioral hypersensitivity. Molecular pain 2009, 5:6.

65. Kim KY, Yoon YW, Chung JM: Comparison of three rodent neuropathic pain models. Experimental brain research Experimentelle Hirnforschung 1997, 113(2):200-6.

66. Gottrup H, Juhl G, Kristensen AD, Lai R, Chizh BA, Brown J, Bach FW, Jensen TS: Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 2004, 101(6):1400-8.

67. Reginster JY: The prevalence and burden of arthritis. Rheumatology (Oxford England) 2002, 41:3-6.

68. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. European journal of pain (London, England) 2006, 10(4):287-333.

69. Urch CE, Donovan-Rodriguez T, Dickenson AH: Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain 2003, 106(3):347-56.

70. Donovan-Rodriguez T, Dickenson AH, Urch CE: Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neuroscience letters 2004, 360(1–2):29-32.

71. Donovan-Rodriguez T, Dickenson AH, Urch CE: Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology 2005, 102(1):132-40.

72. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ: Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain 2007, 128(3):272-82.